Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: Implications for dopamine receptor down-regulation and dopamine release

Journal of Neurochemistry

Volumn 102, Issue 5, 2007, Pages 1548-1560

  Mizoguchi, Hiroyuki ^a,b   Yamada, Kiyofumi ^a,b   Mouri, Akihiro ^a   Niwa, Minae ^a   Mizuno, Tomoko ^a   Noda, Yukihiro ^a,d   Nitta, Atsumi ^a   Itohara, Shigeyoshi ^e   Banno, Yoshiko ^c   Nabeshima, Toshitaka ^a,d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MEIJO UNIVERSITY   (Japan)

^e RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Dopamine; Dopamine receptor; Matrix metalloproteinase; Methamphetamine; Tissue inhibitor of matrix metalloproteinase

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MATRIX METALLOPROTEINASE; METHAMPHETAMINE; OLIGONUCLEOTIDE; SULFUR 35; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR DOWN REGULATION; REWARD; STIMULATION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE AGENTS; DOWN-REGULATION; DRUG INTERACTIONS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MATRIX METALLOPROTEINASES; METHAMPHETAMINE; MICRODIALYSIS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; OLIGONUCLEOTIDES, ANTISENSE; PROTEASE INHIBITORS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; REWARD; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

MUS; RATTUS;

EID: 34547909242     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04623.x     Document Type: Article

References (46)

1. Asahi M., Wang X., Mori T., Sumii T., Jung J. C., Moskowitz M. A., Fini M. E. Lo E. H. (2001) Effects of matrix metalloproteinases-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724 7732.
2. Berke J. Hyman S. T. (2000) Addiction, dopamine, and the molecular mechanisms of memory. Neuron 25, 515 532.
3. Beyer C. E. Steketee J. (2002) Cocaine sensitization: modulation by dopamine D2 receptors. Cereb. Cortex 12, 526 535.
4. Bilousova T. V., Rusakov D. A., Ethell D. W. Ethell I. M. (2006) Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J. Neurochem. 97, 44 56.
5. 2+ influx and neurite growth in response to purified N-cadherin and laminin. J. Cell Biol. 127, 1461 1475.
6. Bowers M. S., McFarland K., Lake R. W., Peterson Y. K., Lapish C. C., Gregory M. L., Lanier S. M. Kalivas P. W. (2004) Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron 42, 269 281.
7. 2+-evoked release of [3H]-dopamine from striatal synaptosomes by dopamine (D2) agonists and antagonists. J. Pharmacol. Exp. Ther. 241, 27 33.
8. Frankin K. B. J. Paxinos G. (1997) The mouse brain in stereotaxic coordinates. Academic, San Diego.
9. Freyer A. M., Bilington C. K., Penn R. B. Hall I. P. (2004) Extracellular matrix modulates β2-adrenergic receptor signaling in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 31, 440 445.
10. Goldstein R. Z. Volkow N. D. (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159, 1642 1652.
11. Hashimoto T., Matsumoto M. M., Li J. F., Lawton M. T. Young W. L 2005) Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurology 5, 1.
12. Itoh T., Ikeda T., Gomi H., Nakao S., Suzuki T. Itohara S. (1997) Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinases 2)-deficient mice. J. Biol Chem. 272, 22389 22392.
13. Kaczmarek L., Lapinska-Dzwonek J. Szymczak S. (2002) Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J. 21, 6643 6648.
14. D-aspartate receptor function requires α-neurexins. Proc. Natl Acad. Sci. USA 101, 2607 2612.
15. Khokha R., Waterhouse P., Yagel S., Lala P. K., Overall C. M., Norton G. Denhardt D. T. (1989) Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243, 947 950.
16. Koivunen E., Arap W., Valtanen H. et al. (1999) Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768 774.
17. Lee S. R., Tsuji K., Lee S. R. Lo E. H. (2004) Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J. Neurosci. 24, 671 678.
18. Lindgren N., Xu Z-Q., Herrera-M M., Haycock J., Hokfelt T. Fisone G. (2001) Dopamine D2 receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur. J. Neurosci. 13, 773 780.
19. Mannello F. Gazzanelli G. (2001) Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 6, 479 482.
20. Mizoguchi H., Yamada K., Mizuno M., Mizuno T., Nitta A., Noda Y. Nabeshima T. (2004) Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol. Pharmacol. 65, 1293 1301.
21. Mizoguchi H., Yamada K., Niwa M., Mouri A., Mizuno T., Noda Y., Nitta A., Itohara S., Banno Y. Nabeshima T. (2007) Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9 deficient mice. J. Neurochem. 100, 1579 1588.
22. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., Noda Y., Nitta A. Nabeshima T. (2004) The tissue plasminnogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc. Natl Acad. Sci. USA 101, 3650 3655.
23. Nagai T., Noda Y., Ishikawa K., Miyamoto Y., Yoshimura M., Ito M., Takayanagi M., Takuma K., Yamada K. Nabeshima T. (2005) The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J. Neurochem. 92, 660 667.
24. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., Costa R. M., Silva A. J., Kaczmarek L. Huntley G. W. (2006) Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 15, 1923 1934.
25. Nakagawa T., Kubota T., Kabut M., Sato K., Kawano H., Hayakawa T. Okada Y. (1994) Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J. Neurosurg. 81, 69 77.
26. Nakajima A., Yamada K., Nagai T. et al. (2004) Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J. Neurosci. 24, 2212 2225.
27. Nestler E. J. (2001) Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119 128.
28. Paxinos G. Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic, New York.
29. Reeves T., Prins M. L., Zhu J. P., Povlishock J. T. Phillips L. L. (2003) Matrix metalloproteinases inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus. J. Neurosci. 12, 10182 10189.
30. Rivera S., Tremblay E., Timsit S., Canals O., Ben-Ari Y. Khrestchatisky M. (1997) Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J. Neurosci. 17, 4223 4235.
31. Robinson T. E. Kolb B. (1997) Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 17, 8491 8497.
32. Rosenberg G. A., Kornfeld M., Estrada E., Kelly R. O., Liotta L. A. Stetler-Stevenson W. G. (1992) TIMP-2 reduces proteolytic opening of blood-brain barrier by IV collagenagse. Brain Res. 56, 203 207.
33. Shippenberg T. S. Heidbreder C. h. (1995) Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J. Pharmacol. Exp. Ther. 273, 808 815.
34. Smith G. N. J., Brandt K. D. Hasty K. A. (1996) Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum. 39, 235 244.
35. Sternlicht M. D. Werb Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463 516.
36. Strongin A. Y., Collier I., Bannikov G., Marmer B. L., Grant G. A. Goldberg G. I. (1995) Mechanism of cell surgace activation of 72-kDa type IV collagenase Isolation of the activated form of the membrane metalloproteinases. J. Biol. Chem. 270, 5331 5338.
37. Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S. Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102 4108.
38. Sunderland W. J., Son Y. J., Miner J. H., Sanes J. R. Carlson S. S. (2000) The presynaptic calcium channel is part of a transmembrane complex linking a synaptic laminin (α4β2γ1) with non-erythroid spectrin. J. Neurosci. 20, 1009 1019.
39. Szklarczyk A., Lapinska J., Rylski M., Mckay R. D. Kaczmarek L. (2002) Matrixmetalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 22, 920 930.
40. Uitto V. J., Firth J., Nip L. Golub L. (1994) Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann. NY Acad. Sci. 732, 140 151.
41. Ushkaryov Y. A., Petrenko A. G., Geppert M. Sudhof T. C. (2002) Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. Science 257, 50 56.
42. Vaillant C., Didier-Bazes M., Hurter A., Bein M. F. Thomasset N. (1999) Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J. Neurosci. 19, 4994 5004.
43. Wright J. W., Reichert J. R., Davis C. J. Harding J. W. (2002) Neural plasticity and the brain renin-angiotensin system. Neurosci. Biovehav. Rev. 26, 529 552.
44. Yamada K., Nagai T. Nabeshima T. (2005) Drug dependence, synaptic plasticity, and tissue plasminogen activator. J. Pharmacol. Sci. 97, 157 161.
45. Yong V. W., Power C., Forsyth P. Edwards D. R. (2001) Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502 511.
46. Zhang J. W. Gottschall P. E. (1997) Zymographic measurement of gelatinase activiy in brain tissue after detergent extrqaction and affinity-support purification. J. Neurosci. Methods 76, 15 20.